Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,726 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection.
Opravil M, Sasadeusz J, Cooper DA, Rockstroh JK, Clumeck N, Clotet B, Montaner J, Torriani FJ, Depamphilis J, Dieterich DT. Opravil M, et al. Among authors: montaner j. J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):36-49. doi: 10.1097/QAI.0b013e31815ac47d. J Acquir Immune Defic Syndr. 2008. PMID: 18156990 Clinical Trial.
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H Jr, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT; APRICOT Study Group. Torriani FJ, et al. Among authors: montaner j. N Engl J Med. 2004 Jul 29;351(5):438-50. doi: 10.1056/NEJMoa040842. N Engl J Med. 2004. PMID: 15282351 Free article. Clinical Trial.
Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
Hoen B, Cooper DA, Lampe FC, Perrin L, Clumeck N, Phillips AN, Goh LE, Lindback S, Sereni D, Gazzard B, Montaner J, Stellbrink HJ, Lazzarin A, Ponscarme D, Staszewski S, Mathiesen L, Smith D, Finlayson R, Weber R, Wegmann L, Janossy G, Kinloch-de Loes S; QUEST Study Group. Hoen B, et al. Among authors: montaner j. Clin Infect Dis. 2007 Aug 1;45(3):381-90. doi: 10.1086/519428. Epub 2007 Jun 26. Clin Infect Dis. 2007. PMID: 17599319 Free article.
Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks.
Trottier B, Walmsley S, Reynes J, Piliero P, O'Hearn M, Nelson M, Montaner J, Lazzarin A, Lalezari J, Katlama C, Henry K, Cooper D, Clotet B, Arastéh K, Delfraissy JF, Stellbrink HJ, Lange J, Kuritzkes D, Eron JJ Jr, Cohen C, Kinchelow T, Bertasso A, Labriola-Tompkins E, Shikhman A, Atkins B, Bourdeau L, Natale C, Hughes F, Chung J, Guimaraes D, Drobnes C, Bader-Weder S, Demasi R, Smiley L, Salgo MP. Trottier B, et al. Among authors: montaner j. J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):413-21. doi: 10.1097/01.qai.0000185313.48933.2c. J Acquir Immune Defic Syndr. 2005. PMID: 16280695 Clinical Trial.
A randomized, open-label study of a nucleoside analogue reverse transcriptase inhibitor-sparing regimen in antiretroviral-naive HIV-infected patients.
Harris M, Côté H, Ochoa C, Allavena C, Negredo E, Thorne A, Cahn P, Zala C, Raffi F, Clotet B, Singer J, Montaner J; CTN 177 Study Team. Harris M, et al. Among authors: montaner j. J Acquir Immune Defic Syndr. 2009 Mar 1;50(3):335-7. doi: 10.1097/QAI.0b013e3181938fc9. J Acquir Immune Defic Syndr. 2009. PMID: 19242263 Clinical Trial. No abstract available.
Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study).
Negredo E, Moltó J, Burger D, Côté H, Miró O, Ribalta J, Martínez E, Puig J, Ruiz L, Salazar J, López S, Montaner J, Rey-Joly C, Clotet B. Negredo E, et al. Among authors: montaner j. J Acquir Immune Defic Syndr. 2005 Jan 1;38(1):47-52. doi: 10.1097/00126334-200501010-00009. J Acquir Immune Defic Syndr. 2005. PMID: 15608524 Clinical Trial.
Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection.
Montaner J, Yeni P, Clumeck NN, Fätkenheuer G, Gatell J, Hay P, Seminari E, Peeters MP, Schöller-Gyüre M, Simonts M, Woodfall B; TMC125-C203 Study Group. Montaner J, et al. Clin Infect Dis. 2008 Oct 1;47(7):969-78. doi: 10.1086/591705. Clin Infect Dis. 2008. PMID: 18764771 Clinical Trial.
Prospective, randomized, open label trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ treatment-naive subjects with CD4+<200 cell/mm3 in Mexico.
Sierra-Madero J, Villasis-Keever A, Méndez P, Mosqueda-Gómez JL, Torres-Escobar I, Gutiérrez-Escolano F, Juárez-Kasusky I, Magana-Aquino M, Ramos-Santos C, Pérez-Saleme L, Rangel-Frausto S, Antuna-Puente B, Soto-Ramírez LE, Lima V, Belaunzarán-Zamudio F, Crabtree-Ramírez B, Montaner J. Sierra-Madero J, et al. Among authors: montaner j. J Acquir Immune Defic Syndr. 2010 Apr;53(5):582-8. doi: 10.1097/QAI.0b013e3181cae4a1. J Acquir Immune Defic Syndr. 2010. PMID: 20090545 Clinical Trial.
1,726 results